Cardiovascular risk management in adults with diagnosed diabetes in Mexico from 2016–2023: A retrospective analysis of nationally representative surveys
Authors:
- Daniel Ramírez-GarcíaDRDaniel Ramírez-García
- Carlos A. Fermín-MartínezCFCarlos A. Fermín-Martínez
- César Daniel Paz-CabreraCPCésar Daniel Paz-Cabrera
- Arsenio Vargas-VázquezAVArsenio Vargas-Vázquez
- Miriam Teresa López-TerosMLMiriam Teresa López-Teros
- David FloodDFDavid Flood
- Jennifer Manne-GoehlerJMJennifer Manne-Goehler
- Neftali Eduardo Antonio-VillaNANeftali Eduardo Antonio-Villa
- Goodarz DanaeiGDGoodarz Danaei
Preprint
Abstract
BACKGROUND Cardiovascular (CVD) risk factor reduction is a cornerstone of diabetes management. Here, we aimed to estimate the prevalence and determinants of individual and combined CVD risk factor control goals amongst individuals living with diagnosed diabetes in Mexico. METHODS We analyzed Mexican National Health and Nutrition Surveys from 2016-2022 including individuals aged ≥20 years with diagnosed diabetes. We estimated the prevalence of glycemic, blood pressure, cholesterol, and smoking control, as well as combined control achievement according to current guidelines, as well as the prevalence of antihypertensive, statin and diabetes medication use. We also explored determinants of control achievement amongst individuals with diabetes using weighted logistic regression. RESULTS We analyzed data from 2,331 adults with diagnosed diabetes. Glycemic control increased over time reaching 41% (95%CI 30%–52%) by 2022. Blood pressure control remained similar over time reaching 45% (95%CI 35%–55%) in 2022, LDL-C control remained low regardless of the definition (CONCLUSIONS Our results suggest a need to improve comprehensive glycemic and CVD risk factor management for individuals living with diabetes in Mexico to improve diabetes care and reduce risk of adverse outcomes.Keywords
This publication has 40 references indexed in Scilit:
- Diabetes subgroups and sociodemographic inequalities in Mexico: a cross-sectional analysis of nationally representative surveys from 2016 to 2022The Lancet Regional Health - Americas, 2024
- Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016JAMA Internal Medicine, 2019
- Long-term effectiveness of a type 2 diabetes comprehensive care program. The CAIPaDi modelDiabetes Research and Clinical Practice, 2019
- Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort studyThe Lancet Diabetes & Endocrinology, 2018
- Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trialDiabetologia, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysisThe Lancet, 2008
- Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialThe Lancet, 2004